News & Updates

Show Multimedia Only

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

15 Nov 2025

Previous analyses found that body weight reduction does not predict the cardiorenal benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; eg, semaglutide). A pooled post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trials demonstrated that semaglutide improved cardiorenal outcomes in a diverse population of patients with type 2 diabetes (T2D), regardless of prior history of cardiovascular disease (CVD) and baseline body mass index (BMI). The CV benefit remained consistent even when accounting for various degrees of weight loss.

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

15 Nov 2025

CRM syndrome: A new era of integrated disease management

12 Nov 2025 by

Cardiovascular (CV), renal, and metabolic (CRM) conditions are interconnected. Worsening of one condition predicts an increased risk of progression of the others, underscoring the importance of early, multifactorial intervention. In an interview with MIMS Doctor, Professor Melanie Davies from the University of Leicester, UK, called for an integrated approach to CKM care, highlighting current evidence and international guideline updates relevant to clinical practice.

CRM syndrome: A new era of integrated disease management

12 Nov 2025

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

10 Nov 2025

In patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD), subcutaneous (SC) semaglutide Q1W was associated with lower risks of 3-point and 5-point major adverse cardiovascular events (3P- and 5P-MACE) and all-cause mortality vs dulaglutide, according to the real-world REACH study presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting.

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

10 Nov 2025

[Infographics] Expanding roles of semaglutide in CKM syndrome

23 Oct 2025

Semaglutide is a key organ-protective medication for managing cardio-kidney-metabolic (CKM) syndrome. Discover more about positive trial results across seven key components of CKM syndrome, and upcoming data on semaglutide.

[Infographics] Expanding roles of semaglutide in CKM syndrome

23 Oct 2025

Optimizing DM management with early insulinization and novel treatments

14 Oct 2025 by

The global diabetes mellitus (DM) epidemic poses significant health challenges in Asia and the rest of the world. At a symposium, Professor Lawrence Leiter of the University of Toronto, Canada, discussed the critical role of early insulinization to reduce long-term complications. He also shared how long-acting insulin analogue injections, such as insulin degludec (IDeg) and its combination with insulin aspart (IDegAsp), which provide longer time in target glucose range with lower hypoglycaemic risks, may help patients achieve long-term treatment goals.

Optimizing DM management with early insulinization and novel treatments

14 Oct 2025

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

10 Oct 2025 by

Dr Walter Wai-Chee Chan's (Specialist in Cardiology in Hong Kong) cases: one patient with statin-induced autoimmune myositis, and another patient with uncontrolled LDL-C despite maximally tolerated statin + ezetimibe. Find out how these patients responded to and tolerated oral bempedoic acid + ezetimibe fixed-dose combination (FDC) treatment.

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

10 Oct 2025

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025 by

Compared with tirzepatide, subcutaneous semaglutide 2.4 mg is associated with a 57 percent lower risk of revised 3-point major adverse cardiovascular events (3P-MACE; defined as MI, stroke, and all-cause mortality [instead of cardiovascular-related death]) in a population similar to the SELECT trial — patients with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD) but no history of diabetes, according to results of the real-world STEER trial presented at the European Society of Cardiology (ESC) Congress 2025.

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025 by

The American Heart Association defines cardiovascular-kidney-metabolic (CKM) syndrome as the overlap between metabolic, kidney, and cardiovascular diseases (CVDs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, offer benefits that extend beyond glycaemic control and weight loss to cardiorenal protection. In a symposium, Dr Julie Lovshin of the University of Toronto, Canada, shared clinical trial data on once-weekly subcutaneous (SC) semaglutide’s cardiorenal protective effects in different CKM patient populations. She also explored characteristics of optimal candidates for GLP-1 RA treatment.

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

CRM syndrome: A new era of integrated disease management

CRM syndrome: A new era of integrated disease management

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

[Infographics] Expanding roles of semaglutide in CKM syndrome

[Infographics] Expanding roles of semaglutide in CKM syndrome

Optimizing DM management with early insulinization and novel treatments

Optimizing DM management with early insulinization and novel treatments

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

[Infographics] Two patients with dyslipidaemia treated with oral bempedoic acid + ezetimibe FDC

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care